PhRMA, Eli Lilly, other drug companies push back on FDA’s draft guidance about communicating off-label usenews2024-01-12T20:20:29+00:00January 12th, 2024|Endpoints News|
Economists, health policy experts say J&J’s IRA arguments are ‘overly simplistic’news2024-01-12T19:25:07+00:00January 12th, 2024|Endpoints News|
Evaluate buys forecasting group to build out prediction software and servicesnews2024-01-12T19:14:56+00:00January 12th, 2024|Endpoints News|
The Bell Labs of biotech: Stuart Schreiber has billionaire support for new biomedical institute news2024-01-12T16:01:52+00:00January 12th, 2024|Endpoints News|
Insurance giant UnitedHealth shares tumble with higher medical expenses despite strong earningsnews2024-01-12T16:01:25+00:00January 12th, 2024|Endpoints News|
Novartis quietly used a PRV to speed the approval of its new rare blood disorder drugnews2024-01-12T15:42:30+00:00January 12th, 2024|Endpoints News|
Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice’s deal in SEAnews2024-01-12T14:58:24+00:00January 12th, 2024|Endpoints News|
#JPM24: Vertex founder Joshua Boger on surviving downturns, ‘painful’ partnerships, and the importance of culturenews2024-01-12T14:06:56+00:00January 12th, 2024|Endpoints News|
Dyne closes $345M public offering a week after early positive data for dystrophy drugsnews2024-01-12T12:02:00+00:00January 12th, 2024|Endpoints News|
Boehringer Ingelheim allocates €120M to boost production of Jardiance in Greek plantnews2024-01-12T11:48:10+00:00January 12th, 2024|Endpoints News|
